Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression

Depress Anxiety. 2002;15(1):48-51. doi: 10.1002/da.1086.

Abstract

We report on 3 subjects with premenstrual magnification of major depression (PMMD) treated with nefazodone who benefited from a supplement of additional nefazodone premenstrually. During the 6-month study, subjects were given supplements of either additional nefazodone or placebo prior to the expected onset of menses (double-blind crossover design). Symptoms were assessed during the late luteal and follicular phases. All subjects showed significant improvement for the months in which they received nefazodone supplements, but not when given placebo. Premenstrual dose increase is a clinically promising intervention for women who experience PMMD.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antidepressive Agents, Second-Generation / administration & dosage
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Piperazines
  • Premenstrual Syndrome / diagnosis
  • Premenstrual Syndrome / drug therapy*
  • Premenstrual Syndrome / psychology
  • Severity of Illness Index
  • Treatment Outcome
  • Triazoles / administration & dosage
  • Triazoles / therapeutic use*

Substances

  • Antidepressive Agents, Second-Generation
  • Piperazines
  • Triazoles
  • nefazodone